5 Best Shares to Buy Right Now in Australia

Finding the best shares to buy on the ASX requires more than just scanning a screener or chasing whatever is up this week. We focus on companies with strong competitive positioning, visible earnings growth, and a catalyst to drive the share price higher over the next 12 months. Every stock on this list has been through a full research process covering financials, industry dynamics, valuation, and management quality.

We update this page regularly as new research is published. The five stocks below represent our most recent work, ordered from newest to oldest. Each summary covers the key points of the investment case, with a link to the full write-up for those who want the detail.

Last updated 27 August 2026.

Our Top 5 Stocks To Buy Right Now on the ASX

Amcor Plc (ASX: AMC)

Buy, 12-month price target A$81.40 (24.4% upside), ~5.6% forward dividend yield, unfranked. Price target and upside based on prices at time of publication.

Amcor has spent two years being judged on everything except its own volumes, and the June quarter finally put them back at the centre of the story. Comparable volumes rose about 0.5 per cent, the first clear positive inflection after a long stretch of destocking. Because the cost base is largely fixed, the earnings response was much larger than the volume move: group adjusted EBIT of US$836 million was up around 22 per cent on a comparable basis, with Flexibles up about 18 per cent and Rigids up about 24 per cent. Quarterly earnings per share of 123 US cents landed towards the top of the guided range.

The self-help is running ahead of plan alongside it. Amcor delivered about US$285 million of Berry synergies in the year to June against an original year-one expectation of US$260 million, and the three-year target of roughly US$650 million has been reaffirmed. Six small businesses have been agreed for sale for about US$500 million in total, five of which have closed, in a programme the company frames as portfolio optimisation. Net debt to EBITDA finished at 3.5 times with a targeted path to three times by the end of 2027.

The reason the stock has not re-rated on a better quarter is a genuinely messy outlook statement. Amcor is moving its year end from June to December, and guidance for the six-month transition period came in below where the market sat, although about 4 cents per share of that gap is the divested businesses, which consensus appears not to have stripped out yet. Guidance for calendar 2027 is for double-digit earnings growth, which on the bottom of the range is at or slightly ahead of consensus. A weaker six months followed by a year that is at least in line is an awkward thing to headline and a reasonable thing to own while being paid 5.6 per cent to wait. Read the full article on Amcor here.

Life360 Inc (ASX: 360)

Buy, 12-month price target A$30.95 (34.4% upside), no dividend. Price target and upside based on prices at time of publication.

Life360 grew revenue 38 per cent to US$159m in the June quarter and lifted adjusted EBITDA 53 per cent to US$31.1m, and the shares fell 19 per cent on the day. Two things drove that reaction. Monthly active user net additions of 4.6m came in below the pace the full-year guidance needs, and the headline profit beat was flattered by a one-off US$3.6m tariff benefit which, stripped out, leaves the quarter around 5 per cent ahead of consensus rather than 20 per cent.

The parts of the business Life360 controls most directly kept improving. Paying circles grew 185,000, a second-quarter record, with US conversion ticking up from 13.6 per cent to 13.8 per cent, and the Silver and Gold tiers were raised US$2 a month for new US subscribers. Advertising, built on the Nativo platform, more than quadrupled to US$22m and is now large enough to move the group result rather than being a rounding error.

Full-year guidance was retained at US$650-685m of revenue and US$130-140m of adjusted EBITDA, but the profit is weighted heavily to the fourth quarter, with management guiding to a margin above 22 per cent by then against 17 per cent underlying in the second quarter. That shape is the risk. A soft third quarter would leave very little room to recover, and user additions still need to step up from here. With the CDIs already down around 37 per cent over twelve months, we think the risk-reward leans favourably, but the next one or two quarters of user data will matter more than this print. Read the full article on Life360 here.

Breville Group Ltd (ASX: BRG)

Buy, 12-month price target A$37.90 (22.1% upside), ~1.4% forward dividend yield. Price target and upside based on prices at time of publication.

Breville Group sold off this year on fears that SharkNinja’s push into premium espresso machines would commoditise Breville’s best-performing category and squeeze the margin advantage that underpins its valuation. The category-level sales data tells a different story. Both premium brands, Breville and De’Longhi, grew their coffee appliance sales over the period SharkNinja gained share, while mass-market Keurig shrank. The share SharkNinja is taking looks to be coming out of the value end of the category, not out of Breville’s premium position, which is the part of the thesis that actually matters for the multiple the stock should carry.

The other overhang has been margin. FY26 is shaping up as the trough year for gross margin, with a full year of tariff costs absorbed into the cost of goods. Tariff refunds already flowing back, further manufacturing localisation, and a stronger Australian dollar are forecast to claw back around 80 basis points of gross margin by FY28, turning what looks like a structural problem today into a cyclical one that unwinds over the next two years.

On valuation, Breville trades at roughly its own ten-year average earnings multiple, a reasonable starting point rather than a bargain. That compares with Wesfarmers around 42 per cent above its own ten-year average, Nick Scali around 29 per cent above, and JB Hi-Fi around 24 per cent above theirs. Breville is the cheapest of that group relative to its own history, but at close to 29 times forward earnings it is not cheap in absolute terms, so the case here rests on the margin recovery playing out and the SharkNinja scare fading, rather than a re-rating from a depressed starting multiple. Read the full article on Breville here.

ResMed Inc (ASX: RMD)

Buy, 12-month price target A$46.70 (~75% upside), ~1.3% forward dividend yield. Price target and upside based on prices at time of publication.

ResMed is the world’s largest maker of devices and masks for obstructive sleep apnea, dual-listed on the ASX and the New York Stock Exchange with the number one global share position in its core market. The stock has drifted lower over the past two months even as the operating story has improved, leaving it on around 16.9 times forward earnings, roughly two turns below its global medtech peers and six turns below its ASX healthcare peers. Two worries explain the discount, and both look more like sentiment than substance. The first is the fear that GLP-1 weight-loss drugs shrink the CPAP market, yet the patient-flow data shows GLP-1 patients are more likely to start and stay on therapy, not less. The second is the return of Philips to the United States market, which is well understood and already priced.

Underneath the noise, a stack of new growth levers is only now starting to scale. The Noctrix acquisition opens the restless legs market, the AirCurve 11 ventilators move ResMed into chronic respiratory care, the AirMini and a new partnership with Oura widen the cash-pay and screening funnel, and a digital service for the United Kingdom National Health Service adds an offshore revenue line. Layer gross margin expansion onto high single-digit revenue growth and the result is earnings per share growing in the mid-teens out to FY28. The 12-month target of A$46.70 implies around 75 per cent upside, and with a net cash balance sheet and a return on capital in the mid-twenties, the risk and reward is skewed upward. Read the full article on ResMed here.

Worley Ltd (ASX: WOR)

Buy, 12-month price target A$14.75 (about 35% upside), 4.7% forward dividend yield. Price target and upside based on prices at time of publication.

Worley is an Australian-headquartered global engineering and project services firm to the energy, chemicals and resources sectors, with around 50,000 staff across 50 countries. Management used its May 2026 Investor Day to set a medium-term target of double-digit EBITA growth through to FY30, anchored on two strategic shifts. The first is expanding into adjacent complex infrastructure markets like data centres, large-scale power, nuclear and industrial water. The second is capturing more of the project life cycle by moving from engineering-led delivery into procurement and construction.

The wider thesis is supported by a structurally larger addressable market. Cumulative 2026 to 2030 capex across the adjacent infrastructure segments Worley is targeting is 15 to 20 times larger than the existing core, with data centres alone representing approximately US$144 billion per year of global capex against a 20 to 30 per cent compound growth rate. The deeper thesis carries a near-term margin trade-off, but the A$125 million cost-out programme is sized to fully reverse the mix-shift dilution back to a 9.5 per cent group EBITA margin.

The stock trades on 10.2 times next twelve months EV/EBIT, a 21 per cent discount to its 5-year average and 14 per cent below global peers, against a 5-year average premium to peers of 4 per cent. With approximately 27 per cent upside to the institutional price target and a forecast dividend yield stepping from 4.1 per cent in FY26 to 5.1 per cent in FY28, the entry point looks attractive for investors with a multi-year horizon. Read the full article on Worley here.

How We Pick Stocks for This List

Our selection process draws on institutional-grade research combined with our own analysis of each company’s competitive positioning, earnings trajectory, and valuation. We focus on ASX-listed businesses with clear catalysts, strong or improving returns on capital, and management teams with a track record of execution. Every stock on this list carries a Buy rating with a defined price target and investment thesis.

We are not trying to pick the next speculative runner. The companies featured here are profitable, have established market positions, and offer a risk-reward profile that we think makes sense for investors looking to build long-term wealth through Australian equities. We refresh this list as new research is completed, typically every few weeks.

If you would like to discuss any of these names or how they might fit within your portfolio, request a callback or call us on 1300 889 603.